Literature DB >> 26832166

Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26832166     DOI： 10.1038/nrurol.2016.24

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

Authors:  Neal D Shore; Simon Chowdhury; Arnauld Villers; Laurence Klotz; D Robert Siemens; Steve van Os; Nahla Hasabou; Fong Wang; Suman Bhattacharya; Axel Heidenreich
Journal:  Lancet Oncol       Date:  2016-01-14       Impact factor: 41.316
  1 in total
  1 in total

1.  Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.

Authors:  Liang Jin; Wangli Mei; Xiang Liu; Xianchao Sun; Shiyong Xin; Zhen Zhou; Jiaxin Zhang; Bihui Zhang; Ping Chen; Ming Cai; Lin Ye
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.